IsoPSA, a new blood test detects prostate cancer more accurately than the current tests that are available. Two crucial measures like distinguishing cancer from benign conditions and identifying patients with high-risk disease are checked, revealed a team of researchers.
‘IsoPSA differentiates between prostate cancer and benign conditions; and also identifies patients with high-grade disease.’
The research team, led by Eric Klein, conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centres in the U.S. enrolled between August 2015 and December 2016.
“Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,” said Klein.
“Unfortunately, PSA is tissue-specific but not cancer-specific, leading to overdiagnosis and overtreatment of biologically insignificant cancers, which is widely recognized as a key limitation in its clinical utility.”
The study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.
IsoPSA proved significantly superior to PSA in two key indications: discriminating between prostate cancer and benign conditions; and identifying patients with high-grade disease.
The former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.
The results show that if validated and adopted clinically, IsoPSA could significantly reduce the rate of unnecessary biopsies by almost 50 percent.
“The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,” said Dr. Klein. The study is published online in European Urology.